Therapeutic Approach

Archive: December, 2015

Ritter Pharmaceuticals Enters Into a $10 Million Common Stock Purchase Agreement with Aspire Capital Fund

LOS ANGELES (December 21, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has entered into a $10 million common stock purchase agreement (the “Purchase Agreement”) and a registration rights agreement […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD